Cyclopharm Expands US Strategy With New Order, Contract; Shares Up 4%

MT Newswires Live
02/19

Cyclopharm (ASX:CYC) secured a purchase order from the National Institutes of Health and a contract with Texas Health Presbyterian Hospital Dallas, part of Texas Health Resources, according to a Thursday Australian bourse filing.

The company has installed its core radiopharmaceutical product, Technegas, at two sites within the St. Charles Health System, marking its first implementation in the Pacific Northwest, the filing said.

The company's shares jumped almost 4% in recent Thursday trade.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10